Brief: LumiraDx Covid-19 & Flu A/B Rapid Antigen Test Achieves CE Marking
23/12/2021 11:07
Dec 23 (Reuters) - LumiraDx Ltd LMDX.O :
* LUMIRADX COVID-19 & FLU A/B RAPID ANTIGEN TEST ACHIEVES CE
MARKING
* LUMIRADX COVID-19 & FLU A/B RAPID ANTIGEN TEST ACHIEVES CE
MARKING
Source text for Eikon: ID:nPncftbfka
Further company coverage: LMDX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on LumiraDx
See all newsBrief: LumiraDx Announces Its Securities Will Be Suspended From Trading On Nasdaq At The Open Of Business On January 9Th
Roche to buy part of LumiraDx diagnostics platform for $295 million
Brief: LumiraDx- Under Terms Of Certain Loan Agreement, Dated March 23, 2021, The Waiver Period Has Expired As Of Today
Brief: LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
Brief: Willard L. Umphrey Reports 10.31% Stake In Lumiradx Limited As Of Dec 22- SEC Filing